End TB Strategy with a goal of a 90% reduction in TB incidence by 2035. Domestically, the . U.S. government’s Global TB Strategy and the National Action Plan for Combating Multidrug-resistant TB have outlined respective paths to end the TB pandemic. The COVID-19 pandemic impacted all facets of biomedical research and healthcare activities,
World TB Day 2024 – Yes! We Can End TB!
Mar 22, 2024 · There were 602 TB-related deaths in the United States in 2021, the most recent year for which data are available. TB affects the entire world, but more than 95% of TB deaths occur in low- and middle-income countries. Drug-resistant TB accounts for about one in three of all antimicrobial resistance-related deaths globally.
Tuberculosis Basic Research - National Institute of Allergy and ...
Mar 24, 2023 · NIAID supports basic research on Mycobacterium tuberculosis (Mtb), the causative agent of TB, and seeks to understand how the bacterium causes disease in humans. The Institute is accelerating efforts to identify new candidate drugs, vaccines and biomarkers and technologies with diagnostic potential to improve TB diagnosis, treatment, and prevention …
Establishing Preclinical Animal Models to Study Post-TB Lung …
Dec 4, 2024 · NIAID invites research applications to better understand the pathophysiology of long-term lung damage resulting from Mycobacterium tuberculosis (Mtb) and the role of the immune response during tuberculosis treatment through Notice of Special interest (NOSI): Establishing and Utilizing Preclinical Animal Models to Study Post-TB Lung Disease …
World TB Day 2023 – ‘Yes! We Can End TB!’ - National Institute of ...
Each year, on March 24, the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, joins people and organizations from around the globe in marking World Tuberculosis Day. On this day, more than 140 years ago, Dr. Robert Koch announced his discovery that most human tuberculosis (TB) is caused by the bacterium Mycobacterium tuberculosis (Mtb). …
NIH Clinical Trial of Tuberculous Meningitis Drug Regimen Begins
Dec 7, 2023 · A trial of a new drug regimen to treat tuberculous meningitis (TBM) has started enrolling adults and adolescents in several countries where tuberculosis (TB) is prevalent. The trial will include 330 participants aged 15 years and older who have or are likely to have TBM based on signs and symptoms, including people living with and without HIV. Because …
Tuberculosis Diagnosis | NIAID: National Institute of Allergy and ...
Oct 27, 2016 · NIAID supports the development of new and improved diagnostic tools for faster and more accurate diagnosis of early tuberculosis (TB) disease and Mycobacterium tuberculosis (Mtb) infection, to help optimize therapy by identifying drug-resistant strains, and to track the spread of TB in a community. The Institute also encourages researchers to ...
Tuberculosis Research Unit at Rutgers | NIAID: National Institute of ...
Bacterial and Host Heterogeneity in TB latency, persistence and progression (U19AI162598) Project 1: Bacterial and host determinants of progression, manifestations, and consequences of TB; Project leader: Jerrold Ellner; Project 2: Immune Determinants of the Course of Mycobacterium tuberculosis infection and Disease; Project leader: Padmini Salgame
TB Portals Is a Clearinghouse for Tuberculosis Research Data
May 18, 2022 · TB in VR—explore pathology of a TB case study and a molecular model demonstrating drug resistance in TB treatment. TB in 3D—view three-dimensional models for TB, which come from clinical trial image sets in the TB Portals collection. All data within the TB Portals follow the HL7 Fast Healthcare Interoperability Resources standard.
Landmark TB Trial Identifies Shorter-Course Treatment Regimen
Oct 21, 2020 · This regimen is the first successful short-course treatment regimen for drug-susceptible TB disease in almost 40 years. TB is one of the most important global health problems. According to recent estimates from the World Health Organization, 10 million new TB cases and 1.4 million deaths from TB occurred globally in 2019.